Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Third generation oral contraceptives.

× No keyword cloud information.

14 in total

1. Competing interests and controversy about third generation oral contraceptives. BMJ readers should know whose words they read.

Authors: J P Vandenbroucke; F M Helmerhorst; F R Rosendaal
Journal: BMJ Date: 2000-02-05

2. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.

Authors: J Rosing; S Middeldorp; J Curvers; M Christella; L G Thomassen; G A Nicolaes; J C Meijers; B N Bouma; H R Büller; M H Prins; G Tans
Journal: Lancet Date: 1999-12-11 Impact factor: 79.321

Review 3. Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Database and the UK Mediplus database.

Authors: R D Farmer; R A Lawrenson; J C Todd; T J Williams; K MacRae
Journal: Hum Reprod Update Date: 1999 Nov-Dec Impact factor: 15.610

Review 4. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks.

Authors: T M Farley; O Meirik; J Collins
Journal: Hum Reprod Update Date: 1999 Nov-Dec Impact factor: 15.610

5. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.

Authors: S Suissa; W O Spitzer; B Rainville; J Cusson; M Lewis; L Heinemann
Journal: Hum Reprod Date: 2000-04 Impact factor: 6.918

6. Oral contraceptives and fatal pulmonary embolism.

Authors: L Parkin; D C Skegg; M Wilson; G P Herbison; C Paul
Journal: Lancet Date: 2000-06-17 Impact factor: 79.321

7. The risk of venous thromboembolism in users of postcoital contraceptive pills.

Authors: C Vasilakis; S S Jick; H Jick
Journal: Contraception Date: 1999-02 Impact factor: 3.375

8. Risk of idiopathic venous thromboembolism in users of progestagens alone.

Authors: C Vasilakis; H Jick; M del Mar Melero-Montes
Journal: Lancet Date: 1999-11-06 Impact factor: 79.321

9. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.

Authors: H Jick; S S Jick; V Gurewich; M W Myers; C Vasilakis
Journal: Lancet Date: 1995-12-16 Impact factor: 79.321

10. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.

Authors: W O Spitzer; M A Lewis; L A Heinemann; M Thorogood; K D MacRae
Journal: BMJ Date: 1996-01-13

7 in total

4. Balancing benefits and harms in health care: observational data on harm should complement systematic reviews of benefit.

Authors: Jan P Vandenbroucke
Journal: BMJ Date: 2003-09-27

Third generation oral contraceptives.

1. Competing interests and controversy about third generation oral contraceptives. BMJ readers should know whose words they read.

2. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.

Review 3. Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Database and the UK Mediplus database.

Review 4. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks.

5. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.

6. Oral contraceptives and fatal pulmonary embolism.

7. The risk of venous thromboembolism in users of postcoital contraceptive pills.

8. Risk of idiopathic venous thromboembolism in users of progestagens alone.

9. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.

10. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.

1. Pitfalls of pharmacoepidemiology.

2. The third generation pill controversy ("continued").

3. Diane-35 (cyproterone acetate): safety concerns.

4. Balancing benefits and harms in health care: observational data on harm should complement systematic reviews of benefit.

Review 5. A pathway to improved prospective observational post-authorization safety studies.

Review 6. Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients?

7. Prescribing patterns in premenstrual syndrome.